Bead-to-Biology Platform

Beyond Traditional Approaches

B2B Platform

The Next Generation of Direct-to-Biology

Direct-to-Biology (D2B) is a drug discovery approach in which crude reaction mixtures or minimally purified compounds are tested directly in biological assays, without first performing full purification and characterization of every compound.

SpiroChem's Bead-to-Biology Platform is designed to expand the chemical space accessible for rapid biological screening. While traditional direct-to-biology (D2B) approaches typically rely on single-step solution-phase reactions and crude reaction mixtures, Bead-to-Biology enables multistep synthesis on resin, including more sophisticated chemistry.

	D2B	SPC Bead2B
Chemistry scope	Single step Simple chemistry preferred	Multistep Complex chemistry feasible
Purity profile	Crude material	Impurities purged after each chemical step
Chemistry	Solution phase	Solid phase
Scaffold constraints	None	Chemical handle necessary
Client deliverable	Screening plates (up to 1 mg/well)

Main applications for Bead-to-Biology

With the advantages of accessing dozens to hundreds of high-quality compounds per week and removing the purification bottleneck, the Bead-to-Biology platform is particularly valuable for:

High-throughput medicinal chemistry
- Rapid evaluation of large analogue libraries
Hit-to-lead campaigns
- Quickly identifying promising chemical series
Lead optimization
- Accelerating SAR generation through fast iteration
DNA-encoded library (DEL) follow-up
- Testing resynthesized hits rapidly before investing in purification
AI-driven drug discovery
- Quickly validating compounds proposed by computational models
Fragment expansion and fragment optimization
- Generating and screening many derivatives of fragment hits